Cargando…

Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury

OBJECTIVE: To observe the effect of non-alcoholic simple fatty liver disease on drug-induced liver injury caused by tuberculosis. METHODS: We retrospectively analyzed the incidence, characteristics, and risk factors of antituberculosis drug-induced liver injury in 104 patients with initial treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yi-Hui, Guo, Yan, Xu, Hong, Feng, Hui, Chen, Dong-Ya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437261/ https://www.ncbi.nlm.nih.gov/pubmed/34526786 http://dx.doi.org/10.2147/IDR.S326386

Ejemplares similares

Correlation of antituberculosis drug-related liver injury and liver function monitoring: A 12-year experience of the Taiwan Drug Relief Foundation
por: Chih, Lan-Hui, et al.
Publicado: (2013)

Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis
por: Wang, Nannan, et al.
Publicado: (2022)

Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment Challenges
por: Rangel, Maria Adriana, et al.
Publicado: (2017)

The Variant at TGFBRAP1 but Not TGFBR2 Is Associated with Antituberculosis Drug-Induced Liver Injury
por: Zhang, Jingwei, et al.
Publicado: (2019)

Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes
por: Su, Qiang, et al.
Publicado: (2021)

Anxiety and Its Influencing Factors in Patients With Drug-Induced Liver Injury
por: Liu, Yi-Hui, et al.
Publicado: (2022)

GSTM1 and GSTT1 genetic polymorphisms and their association with antituberculosis drug-induced liver injury
por: Chanhom, Noppadol, et al.
Publicado: (2020)

Impacts of Non-alcoholic Fatty Liver Disease on Acute Coronary Syndrome: Evidence and Controversies
por: Shi, Shun-Yi, et al.
Publicado: (2023)

A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury
por: Luangchosiri, Chote, et al.
Publicado: (2015)

Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury
por: Caballano-Infantes, Estefanía, et al.
Publicado: (2021)

Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
por: Chao, Hsu-Wen, et al.
Publicado: (2019)

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Impact of non-alcoholic fatty liver disease and smoking on colorectal polyps
por: Chen, Qin-Fen, et al.
Publicado: (2017)

Genetic Polymorphisms of UDP-Glucuronosyltransferases and Susceptibility to Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis
por: Chen, Xinyu, et al.
Publicado: (2023)

Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
por: Kim, Tae Hyun, et al.
Publicado: (2021)

Novel glucose-lowering drugs for non-alcoholic fatty liver disease
por: Fu, Zuo-Di, et al.
Publicado: (2021)

Predicting Antituberculosis Drug–Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study
por: Zhong, Tao, et al.
Publicado: (2021)

Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease
por: Tapper, Elliot B., et al.
Publicado: (2014)

Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets
por: Ding, Ya-Hui, et al.
Publicado: (2017)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease()
por: Khambu, Bilon, et al.
Publicado: (2018)

Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update
por: Miranda, Cesare, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
por: Han, Dong Wook, et al.
Publicado: (2023)

The protective roles of augmenter of liver regeneration in hepatocytes in the non-alcoholic fatty liver disease
por: Dong, Yuan, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Correction: Predicting Antituberculosis Drug–Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study
por: Zhong, Tao, et al.
Publicado: (2021)

Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease
por: Zambon Azevedo, Vittoria, et al.
Publicado: (2022)

Commentary on “Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease”
por: Kayadibi, Huseyin, et al.
Publicado: (2014)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
por: Yan, Hong-Mei, et al.
Publicado: (2015)

Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
por: Wu, Dongqing, et al.
Publicado: (2021)

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation
por: Gallego-Durán, Rocío, et al.
Publicado: (2022)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

Verapamil induces autophagy to improve liver regeneration in non-alcoholic fatty liver mice
por: Lai, Jian-Lin, et al.
Publicado: (2021)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Ramai, Daryl, et al.
Publicado: (2021)

Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients
por: Yuan, Xian-Xian, et al.
Publicado: (2019)

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
por: Song, Byeong Geun, et al.
Publicado: (2023)

Protective effect of probiotics in patients with non-alcoholic fatty liver disease
por: Cai, Gen-shen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5q2t15c9nlmeeiljiaqcl7bl88